Accelerating Complex Biomarkers, Novel & Multimodal Endpoints to Fuel Drug-Diagnostic Innovations from Bench-to-Bedside for Global Precision Medicine Access
As regulatory headwinds turn to tailwinds, precision medicine is shifting into a new gear.
Evolving FDA approaches to LDTs and 510(k) pathways are removing long-standing friction, coordinated Rx-Dx launches are gaining pace, ctDNA and MRD are advancing as clinically meaningful endpoints, and reimbursement expansion is improving access to high-value genomic testing. At the same time, innovation in multiplex assays, multi-omics platforms, liquid biopsy, digital pathology, spatial biology, and AI-powered diagnostics, are rapidly reshaping the IVD landscape.
Fueled by $60B+ in diagnostic deal-making and strategic partnerships, the 16th World Clinical Biomarkers & Companion Diagnostics Summit returns as the industry's esteemed, end-to-end precision medicine forum. Convening 850+ senior leaders from biopharma, diagnostic, regulatory, healthcare, testing labs and multimodal communities, this meeting will span the full value chain; from biomarker discovery to clinical validation, approval and real-world adoption, across a diverse range of technologies and disease areas.
Now expanded into five focused content tracks, join us in harnessing the speed, scale, and growing complexity of innovation happening in next-generation IVD platforms, multimodal data, and CDx development.
This forum is an industry-targeted event with a very specific focus and I appreciate that this has stayed consistent for the precision medicine community over the years
Global Director, Amgen
A great opportunity to network with professionals in the companion diagnostics field and stay informed on the latest trends, emerging technologies and regulatory challenges
Director, Translational Medicine, AstraZeneca
This forum forges the opportunity to 1) meet with a diverse group of individuals and organizations working in the CDx space, 2) hear about ongoing efforts, challenges and wins, 3) connect with key vendors working in the biomarker and CDx space
Head, Translational Medicine, Pfizer
Register Your Interest for 2026
- Free* to Attend for Biopharma & Academia
- The Globally Leading Biomarker & Companion Diagnostic Forum
- Strategic Rx-Dx Co-Development & Partnership Selection Panels
- Biomarker Panels in Oncology, Hematology, Neurological, Chronic, Autoimmune, & Rare Disease
- Brand-New Case Studies on Digital Pathology, Multimodal Data and AI-Enabled Precision Medicine
- Exclusive Networking & Partnerships Opportunities
2026 Faculty Announcements Coming Soon | 2025 Speakers Included
Expertise Partners Include
Explore Related Events
Explore the New Agenda
Hear the latest imaging, multi-omics, single-cell and functional assays, enhanced by AI-driven digital biomarker strategies, enabling earlier and smarter treatment decisions for oncology, autoimmune, neurological, chronic and rare disease patients
Prioritize Partnering with Us
Take up a partnering slot to stand alongside leading biomarker, diagnostic and technology providers, ensure your brand is front and center, and retain your position as the partner of choice in the ever-expanding precision medicine space
Join 850+ Specialist Experts
Be part of the liveliest Rx-Dx conversations with like-minded industry peers spanning a range of precision therapy modalities, and build high-value connections during dedicated networking sessions designed to foster collaborations